Pall signs Japanese deal for blood screen technology:
This article was originally published in Clinica
Executive Summary
Kawasumi Laboratories of Tokyo is to distribute Pall's eBDS (enhanced Bacterial Detection System) in Japan. Under the exclusive deal, Kawasumi will also be responsible for obtaining Japanese regulatory approval for the technology, which received US FDA clearance in January 2004. eBDS can detect bacteria in platelets derived both from single donors and random donor collection and automatically provide pass/fail results in 30 seconds. Bacteria contaminate between one in 2,000 and one in 5,000 platelets collected worldwide, says Pall. There are about 780,000 platelet collections in Japan every year.